Anti-diabetic and hypolipidemic effects of Sargassum yezoense in db/db mice

Biochemical and Biophysical Research Communications

Volumn 424, Issue 4, 2012, Pages 675-680

  Kim, Su Nam ^a   Lee, Woojung ^a   Bae, Gyu Un ^b   Kim, Yong Kee ^b  

^a Korea Institute of Science and Technology   (South Korea)

^b Sookmyung Women's University   (South Korea)

Author keywords

Dyslipidemia; PPAR ; Sargassum yezoense; Type 2 diabetes mellitus

Indexed keywords

ALGAL EXTRACT; GLUCOSE; GLUCOSE 6 PHOSPHATASE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; ROSIGLITAZONE; SARGASSUM YEZOENSE EXTRACT; UNCLASSIFIED DRUG; UNCOUPLING PROTEIN 3;

ADIPOSE TISSUE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIDIABETIC ACTIVITY; ARTICLE; CONTROLLED STUDY; GLUCONEOGENESIS; GLUCOSE BLOOD LEVEL; GLUCOSE METABOLISM; HEPATOMEGALY; IN VIVO STUDY; LIPID METABOLISM; LIVER METABOLISM; MALE; METABOLIC DISORDER; MOUSE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PHARMACOLOGICAL PARAMETERS; PRIORITY JOURNAL; PROTEIN EXPRESSION; SARGASSUM; WEIGHT GAIN;

ALKENES; ANIMALS; BENZOQUINONES; BODY WEIGHT; DIABETES MELLITUS, TYPE 2; GENE EXPRESSION; GLUCOSE; GLUCOSE TOLERANCE TEST; HEPATOMEGALY; HYPOGLYCEMIC AGENTS; LIPID METABOLISM; LIVER; MALE; MICE; MICE, INBRED C57BL; PPAR ALPHA; PPAR GAMMA; SARGASSUM;

ANIMALIA; MUS; SARGASSUM YEZOENSE;

EID: 84864810540     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2012.07.005     Document Type: Article

References (26)

1. Rathmann W., Giani G. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care 2004, 27:2568-2569. author reply 2569.
2. Kopelman P.G. Obesity as a medical problem. Nature 2000, 404:635-643.
3. Mokdad A.H., Ford E.S., Bowman B.A., Dietz W.H., Vinicor F., Bales V.S., Marks J.S. Prevalence of obesity, diabetes, and obesity-related health risk factors, 2001. JAMA 2003, 289:76-79.
4. Michalik L., Auwerx J., Berger J.P., Chatterjee V.K., Glass C.K., Gonzalez F.J., Grimaldi P.A., Kadowaki T., Lazar M.A., O'Rahilly S., Palmer C.N., Plutzky J., Reddy J.K., Spiegelman B.M., Staels B., Wahli W. International Union of Pharmacology. LXI. Peroxisome proliferator-activated receptors. Pharmacol. Rev. 2006, 58:726-741.
5. Lee C.H., Olson P., Evans R.M. Minireview: lipid metabolism, metabolic diseases, and peroxisome proliferator-activated receptors. Endocrinology 2003, 144:2201-2207.
6. Vidal-Puig A.J., Considine R.V., Jimenez-Linan M., Werman A., Pories W.J., Caro J.F., Flier J.S. Peroxisome proliferator-activated receptor gene expression in human tissues. Effects of obesity, weight loss, and regulation by insulin and glucocorticoids. J. Clin. Invest. 1997, 99:2416-2422.
7. Fonseca V. Effect of thiazolidinediones on body weight in patients with diabetes mellitus. Am. J. Med. 2003, 115(Suppl. 8A):42S-48S.
8. Bunger M., Hooiveld G.J., Kersten S., Muller M. Exploration of PPAR functions by microarray technology - a paradigm for nutrigenomics. Biochim. Biophys. Acta 2007, 1771:1046-1064.
9. Bajaj M., Suraamornkul S., Hardies L.J., Glass L., Musi N., DeFronzo R.A. Effects of peroxisome proliferator-activated receptor (PPAR)-alpha and PPAR-gamma agonists on glucose and lipid metabolism in patients with type 2 diabetes mellitus. Diabetologia 2007, 50:1723-1731.
10. Pickavance L.C., Brand C.L., Wassermann K., Wilding J.P. The dual PPARalpha/gamma agonist, ragaglitazar, improves insulin sensitivity and metabolic profile equally with pioglitazone in diabetic and dietary obese ZDF rats. Br. J. Pharmacol. 2005, 144:308-316.
11. Reifel-Miller A., Otto K., Hawkins E., Barr R., Bensch W.R., Bull C., Dana S., Klausing K., Martin J.A., Rafaeloff-Phail R., Rafizadeh-Montrose C., Rhodes G., Robey R., Rojo I., Rungta D., Snyder D., Wilbur K., Zhang T., Zink R., Warshawsky A., Brozinick J.T. A peroxisome proliferator-activated receptor alpha/gamma dual agonist with a unique in vitro profile and potent glucose and lipid effects in rodent models of type 2 diabetes and dyslipidemia. Mol. Endocrinol. 2005, 19:1593-1605.
12. Harrity T., Farrelly D., Tieman A., Chu C., Kunselman L., Gu L., Ponticiello R., Cap M., Qu F., Shao C., Wang W., Zhang H., Fenderson W., Chen S., Devasthale P., Jeon Y., Seethala R., Yang W.P., Ren J., Zhou M., Ryono D., Biller S., Mookhtiar K.A., Wetterau J., Gregg R., Cheng P.T., Hariharan N. Muraglitazar, a novel dual (alpha/gamma) peroxisome proliferator-activated receptor activator, improves diabetes and other metabolic abnormalities and preserves beta-cell function in db/db mice. Diabetes 2006, 55:240-248.
13. Mittra S., Sangle G., Tandon R., Sharma S., Roy S., Khanna V., Gupta A., Sattigeri J., Sharma L., Priyadarsiny P., Khattar S.K., Bora R.S., Saini K.S., Bansal V.S. Increase in weight induced by muraglitazar, a dual PPARalpha/gamma agonist, in db/db mice. Adipogenesis/or oedema?. Br. J. Pharmacol. 2007, 150:480-487.
14. Adeghate E., Adem A., Hasan M.Y., Tekes K., Kalasz H. Medicinal chemistry and actions of dual and pan PPAR modulators. Open Med. Chem. J. 2011, 5:93-98.
15. Mayer A.M., Rodriguez A.D., Berlinck R.G., Fusetani N. Marine pharmacology in 2007-8: marine compounds with antibacterial, anticoagulant, antifungal, anti-inflammatory, antimalarial, antiprotozoal, antituberculosis, and antiviral activities; affecting the immune and nervous system, and other miscellaneous mechanisms of action. Comp. Biochem. Physiol. C Toxicol. Pharmacol. 2011, 153:191-222.
16. Mayer A.M., Rodriguez A.D., Berlinck R.G., Hamann M.T. Marine pharmacology in 2005-6: marine compounds with anthelmintic, antibacterial, anticoagulant, antifungal, anti-inflammatory, antimalarial, antiprotozoal, antituberculosis, and antiviral activities; affecting the cardiovascular, immune and nervous systems, and other miscellaneous mechanisms of action. Biochim. Biophys. Acta 2009, 1790:283-308.
17. Mayer A.M., Rodriguez A.D., Berlinck R.G., Hamann M.T. Marine pharmacology in 2003-4: marine compounds with anthelmintic antibacterial, anticoagulant, antifungal, anti-inflammatory, antimalarial, antiplatelet, antiprotozoal, antituberculosis, and antiviral activities; affecting the cardiovascular, immune and nervous systems, and other miscellaneous mechanisms of action. Comp. Biochem. Physiol. C Toxicol. Pharmacol. 2007, 145:553-581.
18. Kim S.N., Choi H.Y., Lee W., Park G.M., Shin W.S., Kim Y.K. Sargaquinoic acid and sargahydroquinoic acid from Sargassum yezoense stimulate adipocyte differentiation through PPARalpha/gamma activation in 3T3-L1 cells. FEBS Lett. 2008, 582:3465-3472.
19. Matsuda J., Hosoda K., Itoh H., Son C., Doi K., Hanaoka I., Inoue G., Nishimura H., Yoshimasa Y., Yamori Y., Odaka H., Nakao K. Increased adipose expression of the uncoupling protein-3 gene by thiazolidinediones in Wistar fatty rats and in cultured adipocytes. Diabetes 1998, 47:1809-1814.
20. Emilsson V., O'Dowd J., Wang S., Liu Y.L., Sennitt M., Heyman R., Cawthorne M.A. The effects of rexinoids and rosiglitazone on body weight and uncoupling protein isoform expression in the Zucker fa/fa rat. Metabolism 2000, 49:1610-1615.
21. Zhou G., Myers R., Li Y., Chen Y., Shen X., Fenyk-Melody J., Wu M., Ventre J., Doebber T., Fujii N., Musi N., Hirshman M.F., Goodyear L.J., Moller D.E. Role of AMP-activated protein kinase in mechanism of metformin action. J. Clin. Invest. 2001, 108:1167-1174.
22. Evans R.M., Barish G.D., Wang Y.X. PPARs and the complex journey to obesity. Nat. Med. 2004, 10:355-361.
23. Lehrke M., Lazar M.A. The many faces of PPARgamma. Cell 2005, 123:993-999.
24. Nissen S.E., Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N. Engl. J. Med. 2007, 356:2457-2471.
25. Kermani A., Garg A. Thiazolidinedione-associated congestive heart failure and pulmonary edema. Mayo Clin. Proc. 2003, 78:1088-1091.
26. Lincoff A.M., Wolski K., Nicholls S.J., Nissen S.E. Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of randomized trials. JAMA 2007, 298:1180-1188.